Loading chat...
NY A07409
Bill
Status
3/25/2025
Primary Sponsor
Keith Brown
Click for details
AI Summary
-
Redefines "opioid antagonist" in New York law to include all FDA-approved forms and doses of Naloxone, replacing the previous definition that limited approval to only those medications specifically approved by the state Department of Health
-
Requires the Department of Health to make available all FDA-approved formulations and dosages of Naloxone for opioid overdose response purposes
-
Mandates that any purchase, distribution, or prescription authorization for opioid antagonists must allow choice of any FDA-approved formulation or dosage
-
Updates insurance law to prohibit discrimination against individuals prescribed any approved opioid antagonist, expanding beyond the previous specific references to "Naloxone and Narcan"
-
Requires expenditures for opioid antagonist distribution to be put out for competitive bid under state procurement rules, allowing choice among all available Naloxone formulations
Legislative Description
Includes all FDA approved forms and doses of Naloxone as opioid antagonists in the state definition of opioid antagonists; requires the department of health to approve all forms and doses of Naloxone approved by the FDA as opioid antagonists.
Last Action
referred to health
1/7/2026